BVS:NSD-Bioventus Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 14.16

Change

-0.19 (-1.32)%

Market Cap

USD 0.87B

Volume

0.07M

Avg Analyst Target

USD 20.00 (+41.24%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Bioventus Inc (BVS) Stock Analysis:
Based on the Bioventus Inc stock forecasts from 2 analysts, the average analyst target price for Bioventus Inc is USD 20.00 over the next 12 months. Bioventus Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Bioventus Inc is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, Bioventus Inc’s stock price was USD 14.16. Bioventus Inc’s stock price has changed by -0.47% over the past week, +0.92% over the past month and +0.00% over the last year.

About

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preserv ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

+5.36 (+1.25%)

USD43.36B 84.37 117.62
ALGN Align Technology Inc

+8.03 (+1.64%)

USD41.37B 56.55 48.05
PODD Insulet Corporation

+0.92 (+0.39%)

USD16.15B 2,208.27 199.97
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD Abiomed Inc

+9.64 (+3.30%)

USD13.70B 92.48 46.15
BRKR Bruker Corporation

+0.08 (+0.12%)

USD10.73B 39.93 25.78
TNDM Tandem Diabetes Care Inc

+7.60 (+6.54%)

USD7.67B 356.22 187.52
SWAV ShockWave Medical Inc

-11.24 (-7.20%)

USD5.90B N/A N/A
IART Integra LifeSciences Holdings ..

-0.23 (-0.34%)

USD5.83B 27.08 17.89
LIVN LivaNova PLC

-0.53 (-0.63%)

USD4.51B 77.40 N/A

ETFs Containing BVS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.28% 77% C+ 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.28% 77% C+ 56% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.87B 75% C 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 34.13 47% F 27% F
Price/Book Ratio 5.12 40% F 25% F
Price / Cash Flow Ratio 12.13 24% F 32% F
EV/EBITDA 18.18 52% F 39% F
Management Effectiveness  
Return on Equity 7.31% 82% B- 61% D-
Return on Invested Capital 6.14% 77% C+ 68% D+
Return on Assets 4.08% 86% B 75% C
Debt to Equity Ratio 121.89% 19% F 16% F
Technical Ratios  
Short Ratio 3.73 42% F 32% F
Short Percent 2.11% 69% D+ 56% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.